Rice Hall James & Associates LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 24.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,361,373 shares of the specialty pharmaceutical company’s stock after buying an additional 267,971 shares during the period. Supernus Pharmaceuticals accounts for 2.6% of Rice Hall James & Associates LLC’s holdings, making the stock its largest position. Rice Hall James & Associates LLC’s holdings in Supernus Pharmaceuticals were worth $58,675,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares during the period. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares during the period. Bank of New York Mellon Corp raised its position in shares of Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares during the period. Ranger Investment Management L.P. raised its position in shares of Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares during the period. Finally, State Street Corp raised its position in shares of Supernus Pharmaceuticals by 4.0% in the first quarter. State Street Corp now owns 1,355,319 shares of the specialty pharmaceutical company’s stock worth $42,422,000 after buying an additional 52,091 shares during the period. 94.39% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals, Inc. (SUPN) opened at 40.35 on Friday. Supernus Pharmaceuticals, Inc. has a one year low of $17.25 and a one year high of $44.95. The company’s 50-day moving average is $42.53 and its 200 day moving average is $34.00. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 20.36 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/rice-hall-james-associates-llc-buys-267971-shares-of-supernus-pharmaceuticals-inc-nasdaqsupn.html.

A number of equities analysts have recently commented on SUPN shares. Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $30.00 to $44.00 in a research report on Thursday, June 1st. Jefferies Group LLC lifted their price objective on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. Cowen and Company lifted their price objective on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Supernus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $48.43.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 2,500 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $35.90, for a total value of $89,750.00. Following the sale, the vice president now directly owns 37,500 shares of the company’s stock, valued at approximately $1,346,250. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the sale, the vice president now directly owns 21,209 shares in the company, valued at $952,284.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,291 shares of company stock worth $962,766. Insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.